Risk of Hypoglycemia in Type 2 Diabetes

• Status: Completed
• Trial end date: 2016-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to establish the risk and frequency of non-symptomatic hypoglycemia in type 2 diabetes under previous therapy with glibenclamide. Participants will be monitored via a continuous glucose monitoring system in a standardized clinical setting during day and night time, implementing meals and exercise of moderate intensity performed in the postprandial state.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Giessen
• Collaborator: Merck Sharp & Dohme Corp.
• Treatments: Glyburide

Criteria

Inclusion Criteria:

• Type 2 diabetes on glibenclamide with or without

• Glycated hemoglobin ≤ 7.5%

• Stable dosage for three weeks

Exclusion Criteria:

• HbA1c > 7.5%

• Fasting C-peptide below normal

• Concurrent infectious disease

• Pregnancy

• Malignant disease

• Inability to give informed consent